Epirubicin

Endocrine Gland Neoplasms

Syndax PharmaceuticalsPhase 1Dormant

CC

47/ 100

Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence: 32/ 100
Competitive Position: 95/ 100

Competitive context

1 Active assets in the Endocrine Gland Neoplasms cohort.

Asset / Sponsor	Phase	Rating
Irinotecan Xiaoxiang Chen	Phase 2	BB
DEXAMETHASONE Johnson & Johnson Pharmaceutical Research & Development, L.L.C.	Phase 2	B
Trabectedin Johnson & Johnson Pharmaceutical Research & Development, L.L.C.	Phase 2	B
(+)-VINCRISTINE Xiaoxiang Chen	Phase 2	CCC
Niraparib Xiaoxiang Chen	Phase 2	CCC

View all 12 →

Same molecule, other indications

Epirubicin is also rated in:

Recurrent Breast CarcinomaDormant

BBB

Indicative ·

74 / 100

Lung Non-Small Cell Squamous CarcinomaDormant

BBB

Indicative ·

72 / 100

Advanced/Metastatic Gastroesophageal AdenocarcinomaDormant

BBB

Indicative ·

72 / 100

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.